One gathers CVS Health (CVS +2.01%) is having a bit of a moment. A rather down moment, if the share price is anything to go by. Apparently, the prospect of Medicare Advantage rates being less… generous than anticipated is causing a flutter amongst the investors. One really must ask, do they expect manna from heaven? CVS, you see, owns Aetna, a perfectly respectable, if rather large, health insurance operation. And when insurance operations stumble, well, one anticipates a bit of a wobble.
The question, naturally, is whether this presents a buying opportunity. Or, as I rather suspect, a rather elegant trap for the unwary.
A Most Unfortunate Combination
The Trump administration, it seems, is being… restrained with Medicare Advantage rates for 2027 – a mere 0.09% increase. Analysts, bless their optimistic hearts, were hoping for something in the 4-6% range. A significant difference, wouldn’t you agree? And, rather inconveniently for CVS, over a third of their revenue derives from this healthcare benefits segment. A sluggish performance there rather puts a damper on things, doesn’t it? Especially when one considers they only managed a shade over 4% revenue growth in 2024, despite all the fuss.
And then, of course, there’s the matter of rising medical costs. A tiresome issue, really. They’re nibbling away at the margins, leaving precious little room for error. Single-digit profit margins are, shall we say, not exactly a bastion of financial security. The recent quarter, ending September 30th, saw a rather alarming net loss of nearly $4 billion, largely due to goodwill impairment charges totaling $5.7 billion. One almost feels sorry for the accountants.
A Most Decidedly Unattractive Proposition
One hears that CVS shares enjoyed a rather exuberant 77% rise in 2025, fueled by optimism surrounding the new CEO, David Joyner. A commendable effort, no doubt. However, with a confluence of headwinds gathering, one is inclined to view this as a temporary flourish. The health insurance industry is, shall we say, facing headwinds, and the pharmacy business itself is hardly scintillating. Consumers, you see, have rather more options these days for acquiring their pharmaceuticals.
The stock may appear cheap, trading at a forward price-to-earnings multiple of 10. But a low multiple doesn’t necessarily equate to a good value. The broader macroeconomic picture is, frankly, rather gloomy, and without a significant improvement in margins or growth prospects, CVS simply doesn’t present a compelling buying opportunity. As of Monday, the stock was down 5% year-to-date, and one wouldn’t be surprised to see it drift lower in the coming weeks and months. A rather predictable outcome, really. One might suggest diverting funds towards something a little more… robust. Perhaps a decent claret.
Read More
- 21 Movies Filmed in Real Abandoned Locations
- The 11 Elden Ring: Nightreign DLC features that would surprise and delight the biggest FromSoftware fans
- Gold Rate Forecast
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- 39th Developer Notes: 2.5th Anniversary Update
- 17 Black Voice Actors Who Saved Games With One Line Delivery
- 10 Hulu Originals You’re Missing Out On
- Doom creator John Romero’s canceled game is now a “much smaller game,” but it “will be new to people, the way that going through Elden Ring was a really new experience”
- XRP’s $2 Woes: Bulls in Despair, Bears in Charge! 💸🐻
- TON PREDICTION. TON cryptocurrency
2026-02-05 19:33